XCancer

Combination External Radiation and 177Lu-DOTATATE for Large Gastrointestinal Neuroendocrine Tumors: A Single Arm Pilot Clinical Trial

Description:

This phase I trial tests the safety and effectiveness of stereotactic body radiation therapy (SBRT) followed by 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in treating patients with large well-differentiated grade 1-2 digestive system neuroendocrine tumors that cannot be removed by surgery (unresectable). SBRT is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body.

Sponsor:

Emory University

Phase:

Phase 1

Contacts:

Pretesh Patel, MD

pretesh.patel@emory.edu

404-778-3473

Government Study Link:

NCT07150546 - Click here to see study on

ClinicalTrials.gov

177Lu-DOTATATE

Isotope(s):
Target(s):
  • SSTR+